1. Scrip
  2. >>Business
  3. >>Financing

ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

Cancer Drug Developer Closes Up 11.1%

 
• By Mandy Jackson

ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.

Skyscrapers Cityscape Downtown View, Boston Skyline Buildings. NIght time. IPO hologram.
The positive performance of the year's first two IPOs may drive future offerings • Source: Shutterstock

ArriVent Biopharma, Inc. launched the second biopharmaceutical company initial public offering of 2024, a day after CG Oncology, Inc. became the first drug developer to go public in the US this year. While ArriVent did not almost double its valuation in its first day of trading like its predecessor, the company’s IPO was well received, with its share price closing above the offering price in its first day of trading – another positive sign that investors are feeling confident about the industry again.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 
• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

 
• By Sushmita Panda

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Alis Biosciences Launches To Free Cash From Stalled-Out Biotechs

 
• By Mandy Jackson

As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.

More from Business

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Regeneron To Expand US Manufacturing, Citing Commercial And Clinical Expansion

 
• By Alaric DeArment

The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.